n Cardiovascular Journal of South Africa - Ezetimibe offers new opportunity to lower LDL-C to target levels : drug trends in cardiology

Volume 16, Issue 3
  • ISSN : 1680-0745



Extracted from text ... 174 CARDIOVASCULAR JOURNAL OF SOUTH AFRICA Vol 16, No. 3, May/June 2005 Ezetimibe (Ezetrol), a unique selective inhibitor of cholesterol absorption, is the first new cholesterol-lowering medication to be introduced, with FDA approval, in South Africa over the past 15 years. It offers the clinician an opportunity to lower LDL cholesterol by 65 to 80% in co-administration with a potent statin, such as atorvastatin or rosuvastatin. Prof. Derick Raal, head of the Lipid Clinic, University of the Witwatersrand and Johannesburg General Hospital, pointed out at the announcement of Ezetrol's availability on the South African market that ezetimibe is extremely well tolerated ..

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error